Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel

A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era